Evidence map›Paper›PMID 39334335›Full record

ArticleBMC oral health2024

Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients.

Ahmed A Al-Kubaisi, Maysam Abdulrahman Ghazi, Nisreen Salah Majeed, Ekram R Aldelaimi, Hamid H Enezei

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06529588 (Soluble Urokinase Plasminogen Activator Receptor), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06529588 completednot on this map

Soluble Urokinase Plasminogen Activator Receptor (suPAR) is a Potential Biomarker of Stage III-IV, Grade C Periodontitis Through the Impact of Post-radiotherapy on Head and Neck Cancer Patients

TypeobservationalSponsorAl-Maarif University CollegeRan2022 to 2023Enrolled150ConditionsHead and Neck Cancer, Chronic Periodontitis, Radiotherapy Side EffectArmsRadiation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ahmed A Al-KubaisiDepartment of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Al Anbar, 31001, Iraq. ahmed.amer@uoa.edu.iq.ORCID https://orcid.org/0009-0002-6874-6346
Maysam Abdulrahman GhaziDepartment of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Al Anbar, 31001, Iraq.
Nisreen Salah MajeedDepartment of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Al Anbar, 31001, Iraq.
Ekram R AldelaimiDepartment of Periodontology, Al-Anbar Health Directorate, Ministry of Health, Anbar, 31001, Iraq.
Hamid H EnezeiDepartment of Oral and Maxillofacial Surgery, College of Dentistry, University of Anbar, Ramadi, Anbar, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis.

methodsThe study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP + HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.

resultsStage and grade of periodontitis were stage III-IV, grade C in patients (CP + HNC post-RT), stage I-III, grade A/B in patients (CP without HNC), and absent in (healthy). Chronic periodontitis with HNC post-RT patients presented a significantly higher proportion of suPAR levels (506.7 pg/ml) compared to chronic periodontitis without HNC and healthy controls (423.08 pg/ml and 255.9 pg/ml), respectively. A significant positive correlation was found between serum suPAR levels and CAL, PPD, PI, and GBI in the periodontal disease groups. ROC results of suPAR (AUC = 0.976 for CP + HNC post-RT, AUC = 0.872 for CP without HNC). Hyposalivation appeared in patients (CP + HNC post-RT; 0.15 [0.11-0.23] ml/min, P = 0.001) and (CP without HNC; 0.30 [0.25-0.41] ml/min, P = 0.001), compared to healthy controls; 0.35 [0.28-0.54] ml/min, P = 0.001).

conclusionThe study showed a significant elevation in serum suPAR levels in CP + HNC post-RT patients compared to the CP without HNC and control groups. CLINICAL

trial registrationThe study was registered retrospectively; clinicaltrials.gov identifier: NCT06529588. Date of registration: July 31, 2024 https://clinicaltrials.gov/study/NCT06529588 .

Indexed as

BiomarkersChronic PeriodontitisHead and Neck NeoplasmsReceptors, Urokinase Plasminogen ActivatorAdultAgedCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPeriodontal IndexBiomarkersReceptors, Urokinase Plasminogen ActivatorChronic periodontitisHead and neck cancerRadiotherapysuPAR

Identifiers

PMID39334335
PMCPMC11438140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.